TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06210152

Intervention type: DEVICE
Intervention: Radial Extracorporeal Shockwave Therapy
Description: Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.

Intervention type: DEVICE
Intervention: Sham Extracorporeal Shockwave Therapy
Description: Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
Study: NCT05148052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality exergames
Description: Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality exergames
Description: Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy
Description: Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy
Description: Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
Study: NCT06240351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib is a Janus kinase (JAK) inhibitor
Study: NCT04863365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: A matching placebo ophthalmic solution, 3 drops daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 ophthalmic solution
Description: PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
Study: NCT05588011

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo
Description: A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LivaNova
Description: A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
Study: NCT05937503

Intervention type: OTHER
Group type: OTHER
Intervention: manual therapy
Description: The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physiotherapy
Description: Control group will only receive conventionel physiotherapy intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: Control group will only receive conventionel physiotherapy intervention.
Study: NCT02476474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 cm start of resection
Description: Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cm start of resection
Description: Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
Study: NCT05632276

Intervention type: DEVICE
Group type: OTHER
Intervention: ConvaFoam
Description: ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
Study: NCT06544031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Nutrition Education Program
Description: The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Nutrition Education Program
Description: The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
Study: NCT04788862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum infected erythrocytes
Description: Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum infected erythrocytes
Description: Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
Study: NCT06323863

Intervention type: PROCEDURE
Intervention: stapedectomy
Description: stapes removal and replacement by a prosthesis

Intervention type: RADIATION
Intervention: ultra high resolution CT
Description: imaging study
Study: NCT04046172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supra/sub gingival root surface debridement
Description: The test group will undergo Intensive periodontal treatment (IPT)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: supra-gingival scaling and polishing
Description: Control group will receive the Control periodontal treatment (CPT).
Study: NCT05218226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
Study: NCT04515524

Intervention type: OTHER
Intervention: Non-Interventional
Description: No study treatment will be administered in this study
Study: NCT06316973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1103
Description: CS-1103 for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Sterile Saline for Injection
Study: NCT05266560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
Study: NCT06182696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OriCAR-017
Description: GPCRC5D-directed chimeric antigen receptor modified T cells
Study: NCT05788133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment and screening by neuropsychological tests on humanoid robot
Description: treatment and screening by neuropsychological tests on humanoid robot
Study: NCT04887012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK
Description: lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
Study: NCT06504069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial VR intervention
Description: A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
Study: NCT05771233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention
Description: First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared.
Study: NCT04777162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: For included participants, tislelizumab would be administrated 200mg q3w iv.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
Study: NCT04675268

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oximetry
Description: A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
Study: NCT05603403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiatop
Description: 1 sachet orally, 2 times a day, for 42 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet orally, 2 times a day, for 42 days
Study: NCT05118802

Intervention type: OTHER
Intervention: Interview
Description: Attends Interviews

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete Survey
Study: NCT05718037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zoster Vaccine Recombinant, Adjuvanted
Description: 0.5mL, Intramuscular
Study: NCT06291142

Intervention type: DEVICE
Intervention: Observation - Nailfold capillaroscopy
Description: Nailfold capillaroscopy examination
Study: NCT05923788

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T1 mapping measurement
Description: T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T1 mapping measurement
Description: T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
Study: NCT06099977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Binaural sound
Description: Binaural sound: Binaural sound will be applied.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only headphone without sound will be applied.
Study: NCT05696574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol
Description: Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Description: Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
Study: NCT04485195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vernakalant
Description: an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procainamide
Description: 15 mg/kg in 500 mL of normal saline given over 60 minutes
Study: NCT06187168

Intervention type: PROCEDURE
Intervention: exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.
Description: This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
Study: NCT05235919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 30 minutes rTMS session 5 days/week for 3 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 30 minutes sham stimulation 5 days/week for 3 weeks.
Study: NCT06362863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition biscuits
Description: Addition of enteral nutritional biscuits to existing pharmacological treatment.
Study: NCT05567770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinium-J591
Description: Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinium-J591
Description: Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Study: NCT06516744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bye Bye Bloat Capsules
Description: Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
Study: NCT05843318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water intake and weight control in older adults - Premeal Water + hypocaloric diet
Description: Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water intake and weight control in older adults - Total Daily Water + hypocaloric diet
Description: Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Intake and weight control in older adults - hypocaloric diet alone
Description: Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
Study: NCT05085275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate 1 GM Oral Tablet [AURYXIA]
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Study: NCT05278078

Intervention type: OTHER
Group type: OTHER
Intervention: psychological support
Description: psychological support will be given to the patients in the experimental group.

Intervention type: OTHER
Group type: OTHER
Intervention: nutritional education
Description: nutritional education will be given to the patients in the experimental group.

Intervention type: OTHER
Group type: OTHER
Intervention: psychological support and nutritional education
Description: psychological support and nutritional education will be given to the patients in the experimental group.

Intervention type: OTHER
Group type: OTHER
Intervention: no intervation
Description: No intervention will be applied to the control group
Study: NCT06110429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactate, Sodium
Description: Isovolemic and osmotic infusion Comparison of osmotic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Study: NCT05612633

Intervention type: DRUG
Group type: OTHER
Intervention: zelavespib
Description: Oral zelavespib 100 mg will be administered once daily
Study: NCT05920408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXS21546
Description: EXS21546 Granule in Capsule
Study: NCT05693454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration with NaCl
Description: Local wound infiltration at the end of spine surgery with NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with Ropivacain
Description: Local wound infiltration at the end of spine surgery with Ropivacain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with a combination of Levobupivacaine and Tramadol
Description: Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
Study: NCT05269030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Topical
Description: Ivermectin 1% in a dose of two drops per nostril twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Nasal
Description: 64 µg per puff in a dose of 1 puff for each nostril twice daily.
Study: NCT06172400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine, Combinations
Description: Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine, Combinations
Description: Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
Study: NCT05779878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial arm pull technique
Description: Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
Study: NCT05689307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIVA-MVP
Description: Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.